Sumitomo Mitsui DS Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-20,387
| Closed | -$1.1M | – | 773 |
|
|
2025
Q3 | $1.1M | Hold |
20,387
| – | – | 0.01% | 603 |
|
|
2025
Q2 | $1.12M | Sell |
20,387
-256
| -1% | -$15.1K | 0.01% | 601 |
|
|
2025
Q1 | $1.46M | Sell |
20,643
-120
| -0.6% | -$8.07K | 0.01% | 554 |
|
|
2024
Q4 | $1.36M | Hold |
20,763
| – | – | 0.01% | 572 |
|
|
2024
Q3 | $1.46M | Buy |
20,763
+3,939
| +23% | +$329K | 0.02% | 557 |
|
|
2024
Q2 | $1.39M | Buy |
16,824
+117
| +0.7% | +$9.74K | 0.02% | 536 |
|
|
2024
Q1 | $1.46M | Sell |
16,707
-54
| -0.3% | -$4.83K | 0.02% | 519 |
|
|
2023
Q4 | $1.62M | Buy |
16,761
+73
| +0.4% | +$6.46K | 0.02% | 499 |
|
|
2023
Q3 | $1.48M | Sell |
16,688
-41
| -0.2% | -$3.65K | 0.02% | 473 |
|
|
2023
Q2 | $1.45M | Sell |
16,729
-19
| -0.1% | -$1.79K | 0.02% | 475 |
|
|
2023
Q1 | $1.63M | Buy |
16,748
+2,275
| +16% | +$236K | 0.03% | 426 |
|
|
2022
Q4 | $1.5M | Hold |
14,473
| – | – | 0.03% | 426 |
|
|
2022
Q3 | $1.23M | Buy |
14,473
+117
| +0.8% | +$10.4K | 0.03% | 448 |
|
|
2022
Q2 | $1.19M | Buy |
14,356
+2,584
| +22% | +$206K | 0.03% | 438 |
|
|
2022
Q1 | $908K | Sell |
11,772
-99
| -0.8% | -$8.28K | 0.02% | 540 |
|
|
2021
Q4 | $1.05M | Buy |
11,871
+2,218
| +23% | +$183K | 0.02% | 518 |
|
|
2021
Q3 | $746K | Sell |
9,653
-65
| -0.7% | -$5.13K | 0.02% | 575 |
|
|
2021
Q2 | $810K | Hold |
9,718
| – | – | 0.02% | 560 |
|
|
2021
Q1 | $733K | Hold |
9,718
| – | – | 0.02% | 560 |
|
|
2020
Q4 | $852K | Hold |
9,718
| – | – | 0.02% | 501 |
|
|
2020
Q3 | $739K | Sell |
9,718
-45
| -0.5% | -$4.55K | 0.02% | 492 |
|
|
2020
Q2 | $1.2M | Buy |
9,763
+15
| +0.2% | +$1.49K | 0.04% | 358 |
|
|
2020
Q1 | $823K | Buy |
9,748
+70
| +0.7% | +$6.03K | 0.03% | 377 |
|
|
2019
Q4 | $818K | Hold |
9,678
| – | – | 0.03% | 475 |
|
|
2019
Q3 | $652K | Buy |
9,678
+1,564
| +19% | +$120K | 0.02% | 501 |
|
|
2019
Q2 | $694K | Sell |
8,114
-2,680
| -25% | -$229K | 0.03% | 463 |
|
|
2019
Q1 | $958K | Buy |
10,794
+11
| +0.1% | +$1.02K | 0.02% | 531 |
|
|
2018
Q4 | $918K | Buy |
10,783
+205
| +2% | +$19.5K | 0.02% | 483 |
|
|
2018
Q3 | $1.02M | Sell |
10,578
-273
| -3% | -$27.3K | 0.02% | 506 |
|
|
2018
Q2 | $1.02M | Hold |
10,851
| – | – | 0.02% | 501 |
|
|
2018
Q1 | $879K | Sell |
10,851
-1,133
| -9% | -$97.2K | 0.01% | 545 |
|
|
2017
Q4 | $1.07M | Sell |
11,984
-250
| -2% | -$21.7K | 0.02% | 501 |
|
|
2017
Q3 | $1.14M | Hold |
12,234
| – | – | 0.02% | 443 |
|
|
2017
Q2 | $1.11M | Sell |
12,234
-985
| -7% | -$89.6K | 0.02% | 453 |
|
|
2017
Q1 | $1.16M | Buy |
13,219
+1,291
| +11% | +$115K | 0.02% | 441 |
|
|
2016
Q4 | $988K | Buy |
11,928
+811
| +7% | +$69.7K | 0.02% | 449 |
|
|
2016
Q3 | $1.03M | Hold |
11,117
| – | – | 0.02% | 430 |
|
|
2016
Q2 | $864K | Buy |
11,117
+218
| +2% | +$18.5K | 0.03% | 439 |
|
|
2016
Q1 | $898K | Buy |
10,899
+105
| +1% | +$8.54K | 0.03% | 431 |
|
|
2015
Q4 | $1.13M | Buy |
10,794
+30
| +0.3% | +$3.13K | 0.04% | 360 |
|
|
2015
Q3 | $1.13M | Sell |
10,764
-140
| -1% | -$18.7K | 0.04% | 373 |
|
|
2015
Q2 | $1.49M | Sell |
10,904
-650
| -6% | -$80.5K | 0.05% | 335 |
|
|
2015
Q1 | $1.44M | Sell |
11,554
-110
| -0.9% | -$11.7K | 0.04% | 367 |
|
|
2014
Q4 | $1.05M | Sell |
11,664
-12,200
| -51% | -$1.01M | 0.03% | 452 |
|
|
2014
Q3 | $1.72M | Sell |
23,864
-4,365
| -15% | -$287K | 0.05% | 333 |
|
|
2014
Q2 | $1.76M | Sell |
28,229
-2,900
| -9% | -$175K | 0.05% | 340 |
|
|
2014
Q1 | $2.12M | Buy |
31,129
+14,959
| +93% | +$1.1M | 0.06% | 279 |
|
|
2013
Q4 | $1.14M | Buy |
16,170
+9
| +0.1% | +$611 | 0.03% | 464 |
|
|
2013
Q3 | $1.17M | Buy |
16,161
+415
| +3% | +$27.6K | 0.03% | 443 |
|
|
2013
Q2 | $878K | Buy |
+15,746
| New | +$981K | 0.02% | 522 |
|
Other funds holding BMRN
Sumitomo Mitsui DS Asset Management's BMRN Position: Q4 2025 in Review
Sumitomo Mitsui DS Asset Management sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 20,387 shares — an estimated $1.1M sold.
Sumitomo Mitsui DS Asset Management first reported a position in BMRN in Q2 2013 and held it in 50 quarters. The position peaked at $2.12M in Q1 2014. 540 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.
- Sumitomo Mitsui DS Asset Management reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Sumitomo Mitsui DS Asset Management sold 20,387 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $1.1M.
- Sumitomo Mitsui DS Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2013 and held it in 50 quarters.
- Sumitomo Mitsui DS Asset Management's BioMarin Pharmaceuticals position peaked at $2.12M in Q1 2014.
- 540 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.
Based on Sumitomo Mitsui DS Asset Management's 13F filing for Q4 2025, filed 3 Feb 2026.